Glenmark launches AKYNZEO IV for prevention of chemotherapy-induced nausea and vomiting

AKYNZEO IV, a fixed-dose combination of fosnetupitant (235mg) and palonosetron(0.25mg), will be available as a single-dose, ready-to-dilute IV injection

Glenmark Pharmaceuticals is the first to launch in India a unique IV injection formulation, AKYNZEO I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an

an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.

AKYNZEO I.V. is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute I.V. injection. It is administered as a single infusion 30 minutes before the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV. The drug is already being marketed in the EU, the US, and Australia. 

On the occasion of the launch, Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals, said, “At Glenmark, we are unwavering in our pursuit to help patients and clinicians in cancer care. Chemotherapy is the most common form of cancer treatment, with

nausea and vomiting are two of its most debilitating side effects. 

AKYNZEO IV is a convenient,single‐dose, ready‐to‐dilute I.V. injection that covers, both, the acute and the delayed phases of CINV, thereby enabling patients to avoid multiple antiemetic drugs, and improving compliance.”

Helsinn Group CEO, Giorgio Calderari, said, “AKYNZEO I.V would provide a new prophylactic option for patients in India, undergoing chemotherapy and who are at risk of CINV. We are delighted to partner with Glenmark who has an excellent footprint in this region and is trusted with providing the best treatment options for cancer patients.”